These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21254873)

  • 1. Quantitative knowledge-based analysis in compound safety assessment.
    Bureeva S; Nikolsky Y
    Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):287-98. PubMed ID: 21254873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and computational models.
    Wills Q
    Pharmacogenomics; 2007 Aug; 8(8):1081-4. PubMed ID: 17716240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toxicogenomics in predictive toxicology in drug development.
    Suter L; Babiss LE; Wheeldon EB
    Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of network biology on drug toxicology.
    Gautier L; Taboureau O; Audouze K
    Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1409-18. PubMed ID: 23937336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of genomics in preclinical drug safety evaluation.
    Lord PG; Nie A; McMillian M
    Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of new technologies to characterization and prediction of adverse effects.
    Rouquié D; Heneweer M; Botham J; Ketelslegers H; Markell L; Pfister T; Steiling W; Strauss V; Hennes C
    Crit Rev Toxicol; 2015 Feb; 45(2):172-83. PubMed ID: 25615431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective analysis of toxicogenomics in the safety assessment of drug candidates.
    Foster WR; Chen SJ; He A; Truong A; Bhaskaran V; Nelson DM; Dambach DM; Lehman-McKeeman LD; Car BD
    Toxicol Pathol; 2007 Aug; 35(5):621-35. PubMed ID: 17654404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigative safety science as a competitive advantage for Pharma.
    Moggs J; Moulin P; Pognan F; Brees D; Leonard M; Busch S; Cordier A; Heard DJ; Kammüller M; Merz M; Bouchard P; Chibout SD
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1071-82. PubMed ID: 22769724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional analysis of OMICs data and small molecule compounds in an integrated "knowledge-based" platform.
    Nikolsky Y; Kirillov E; Zuev R; Rakhmatulin E; Nikolskaya T
    Methods Mol Biol; 2009; 563():177-96. PubMed ID: 19597786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA perspective on the nonclinical use of the X-Omics technologies and the safety of new drugs.
    Jacobs A
    Toxicol Lett; 2009 Apr; 186(1):32-5. PubMed ID: 18809476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database.
    Ganter B; Snyder RD; Halbert DN; Lee MD
    Pharmacogenomics; 2006 Oct; 7(7):1025-44. PubMed ID: 17054413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathway analysis tools and toxicogenomics reference databases for risk assessment.
    Ganter B; Zidek N; Hewitt PR; Müller D; Vladimirova A
    Pharmacogenomics; 2008 Jan; 9(1):35-54. PubMed ID: 18154447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational toxicology: heading toward more relevance in drug discovery and development.
    Johnson DE; Rodgers AD
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):29-37. PubMed ID: 16445115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to advancing quantitative human health risk assessment of environmental chemicals in the post-genomic era.
    Chiu WA; Euling SY; Scott CS; Subramaniam RP
    Toxicol Appl Pharmacol; 2013 Sep; 271(3):309-23. PubMed ID: 20353796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug safety testing paradigm, current progress and future challenges: an overview.
    Ahuja V; Sharma S
    J Appl Toxicol; 2014 Jun; 34(6):576-94. PubMed ID: 24777877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ArrayTrack: an FDA and public genomic tool.
    Fang H; Harris SC; Su Z; Chen M; Qian F; Shi L; Perkins R; Tong W
    Methods Mol Biol; 2009; 563():379-98. PubMed ID: 19597796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The embryonic stem cell test combined with toxicogenomics as an alternative testing model for the assessment of developmental toxicity.
    van Dartel DA; Piersma AH
    Reprod Toxicol; 2011 Sep; 32(2):235-44. PubMed ID: 21575713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.